



January 22, 2025

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Madam/ Sir,

**Sub: Press Release**

Please find attached Press Release issued by the Company titled:

**“Strides Pharma debuts with a stellar ESG rating of 76/100 in the S&P Global’s  
Corporate Sustainability Assessment (CSA) 2024”**

Thanks & Regards,  
For **Strides Pharma Science Limited**,

**Manjula Ramamurthy**  
**Company Secretary**  
**ICSI Membership No. A30515**

Encl. As above

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700  
Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

## Strides Pharma debuts with a stellar ESG rating of 76/100 in the S&P Global's Corporate Sustainability Assessment (CSA) 2024

- Scored **85/100**, **2.3x** the industry average in **Social**
- Scored **73/100**, **1.8x** the industry average in **Governance**
- Scored **62/100**, **1.8x** the industry average in **Environment**

**Bangalore, India, January 22, 2025** – Strides Pharma Science Limited is pleased to announce that the Company has received an ESG score of 76/100 and CSA score of 75/100 in the Corporate Sustainability Assessment (CSA) Annual Review (vide report dated 20<sup>th</sup> January, 2025) for its debut submission. This accomplishment is a significant milestone in our Environmental, Social, and Governance (ESG) journey and further validates our ongoing commitment to sustainability. With this achievement, Strides has secured a position in the **94<sup>th</sup> percentile** among its peers in the DRG Global Pharmaceuticals industry. **On Customer Relations**, the Company achieved **100<sup>th</sup> percentile**, showcasing its unwavering commitment to exceptional service, strong customer relationships, and the highest standards of satisfaction and trust.

The Company has demonstrated exceptional performance by achieving an ESG score of **76/100**, driven by the Social and Governance Dimensions, which carry the highest weightage, securing the **97<sup>th</sup> percentile**. In Environment dimension, the Company attained a commendable **87<sup>th</sup> percentile**.

**Mr. Arun Kumar, Founder & Executive Chairperson, and Mr. Badree Komandur, MD & Group CEO**, commented, “We are proud to announce that we have received an industry-leading ESG rating from S&P Global on our debut submission. This accomplishment underscores our unwavering commitment to sustainability. It validates our dedication to responsible business practices and reinforces our ongoing efforts to integrate ESG principles across our business operations. As we continue to strengthen and expand our ESG initiatives, we remain focused on creating a lasting, positive impact for all our stakeholders.”

This outstanding performance is underpinned by key material drivers, including Contribution to Societal Healthcare, Human Capital Management, and Corporate Governance, which continue to be pivotal in shaping the company's sustainability excellence. We remain committed to maintaining and further enhancing our ESG performance, striving to set new benchmarks in sustainability and responsible business practices in the years ahead.

### About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company's website at [www.strides.com](http://www.strides.com)

For further information, please contact:

**Institutional Investors**

**Vikesh Kumar**

Group CFO

Email: [investor-relations@strides.com](mailto:investor-relations@strides.com)

**Saurabh Ambaselkar**

Investor Relations - +91 99609 31220

Email: [saurabh.ambaselkar@strides.com](mailto:saurabh.ambaselkar@strides.com)

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi,

Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,  
Bengaluru – 560076

**Corporate Communication**

**Pallavi Panchmatia:** +91 80 6784 0193

Email: [pallavi.panchmatia@strides.com](mailto:pallavi.panchmatia@strides.com)

**Janhavi Bellare:** +91 93228 54508

[Janhavi.bellare@adfactorspr.com](mailto:Janhavi.bellare@adfactorspr.com)

**Syed Talal:** +91 99876 19679

[syed.talal@adfactorspr.com](mailto:syed.talal@adfactorspr.com)